Cargando…
Fetal Toxicity of Immunosuppressive Drugs in Pregnancy
Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306731/ https://www.ncbi.nlm.nih.gov/pubmed/30558290 http://dx.doi.org/10.3390/jcm7120552 |
_version_ | 1783382844131770368 |
---|---|
author | Ponticelli, Claudio Moroni, Gabriella |
author_facet | Ponticelli, Claudio Moroni, Gabriella |
author_sort | Ponticelli, Claudio |
collection | PubMed |
description | Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal risks. Some immunosuppressive drugs are teratogenic and should be replaced even before the pregnancy, while other drugs need to be managed with caution to prevent fetal risks, including miscarriage, intrauterine growth restriction, prematurity, and low birth weight. In particular, the increasing use of biologic agents raises the question of their compatibility with reproduction. In this review we present data on the indication and safety in pregnancy of the most frequently used immunosuppressive drugs. |
format | Online Article Text |
id | pubmed-6306731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63067312019-01-02 Fetal Toxicity of Immunosuppressive Drugs in Pregnancy Ponticelli, Claudio Moroni, Gabriella J Clin Med Review Women affected by autoimmune diseases, organ transplantation, or neoplasia need to continue immunosuppressive treatment during pregnancy. In this setting, not only a careful planning of pregnancy, but also the choice of drugs is critical to preventing maternal complications and minimizing the fetal risks. Some immunosuppressive drugs are teratogenic and should be replaced even before the pregnancy, while other drugs need to be managed with caution to prevent fetal risks, including miscarriage, intrauterine growth restriction, prematurity, and low birth weight. In particular, the increasing use of biologic agents raises the question of their compatibility with reproduction. In this review we present data on the indication and safety in pregnancy of the most frequently used immunosuppressive drugs. MDPI 2018-12-15 /pmc/articles/PMC6306731/ /pubmed/30558290 http://dx.doi.org/10.3390/jcm7120552 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ponticelli, Claudio Moroni, Gabriella Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title_full | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title_fullStr | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title_full_unstemmed | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title_short | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
title_sort | fetal toxicity of immunosuppressive drugs in pregnancy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306731/ https://www.ncbi.nlm.nih.gov/pubmed/30558290 http://dx.doi.org/10.3390/jcm7120552 |
work_keys_str_mv | AT ponticelliclaudio fetaltoxicityofimmunosuppressivedrugsinpregnancy AT moronigabriella fetaltoxicityofimmunosuppressivedrugsinpregnancy |